awgldk
/
wikidata
/
Login
Register
TriplyDB
Wikidata
Browser
Table
SPARQL
Graphs
1
1
Services
1
1
Assets
0
0
Insights
Schema
BETA
Class frequency
Class hierarchy
Q26995810-5D22D23D-299C-4DD6-9387-63B0C71EEEDA
Q26995810-5D22D23D-299C-4DD6-9387-63B0C71EEEDA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26995810-5D22D23D-299C-4DD6-9387-63B0C71EEEDA
Inclusion of placebos and blinding for ascending dose first-in-human studies and other underpowered phase 1 studies has not been justified and on balance is not useful
P2860
Q26995810-5D22D23D-299C-4DD6-9387-63B0C71EEEDA
BestRank
Statement
http://www.wikidata.org/entity/statement/Q26995810-5D22D23D-299C-4DD6-9387-63B0C71EEEDA
rank
NormalRank
type
BestRank
Statement
wasDerivedFrom
b6f31eb4207706373790e08ecf666941c875bd4c
P2860
Evaluation of the cohort size in phase I dose escalation trials based on laboratory data.